PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449A/PT	0		Comp	olete if Known	
INICO		DIOO	001105	Application Number	10/031,180	
	RMATION			Filing Date	January 16, 2002	
STAT	EMENT B	Y APF	PLICANT	First Named Inventor	Alistair Dixon, et al.	
				Group Art Unit		
(L	ise as many she	ets as nec	essary)	Examiner Name		
Sheet	1	of	2	Attorney Docket Number	A0000096-01-SMH	

				U.S. PATENT DOCU	MENTS	
Examiner Initials*	Cite No.1	U.S. Patent Number	Oocument Kind Code ² (If known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Sal		5,155,11		David T. Connor, et al.	10/13/1992	/ Notes reposit
			\rightarrow			
		<u></u>			 	
	\dashv					
			- 		1	
					 	
				/		

						· · · · · · · · · · · · · · · · · · ·
	_4					
4						
$\angle \parallel$						
	•				1	-

				FORE	IGN PATENT DOCUMENTS	\$	-	
Examiner	Cite		Foreign Patent Do	cument	Name of Patentee or	Date of Publication of	Pages, Columns, Lines,	Т
Initials*	No.1	Office ³	Number ⁴	Kind Cade ⁵ (If known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	π
481		WO	98/37881	Al	Alexander J. Bridges	09/03/1998		
		wo	99/01421	A1	Stephen D. Barrett, et al.	01/14/1999		1
		WO	99/01426	Al	Stephen D. Barrett, et al	01/14/1999		1
40		wo	00/35436	A2	David T. Dudley, et al.	06/22/2000	· · · · · · · · · · · · · · · · · · ·	I
								1
		\sqcup						
		\vdash	· · · · · · · · · · · · · · · · · · ·					
								
		Li				I i		1

		1			
Examiner Signature	(on	Mi	14/2	Date Considered	1/28/05

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initiat if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

									_	_
•	Please	type a	plus	sign	(+)	inside	this box	->	1 +	

of

2

Sheet

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

A0000096-01-SMH

Substitute for form 14498/PTO		plete if Known
	Application Number	10/031,180
INFORMATION DISCLOSURE	Filing Date	January 16, 2002
STATEMENT BY APPLICANT	First Named Inventor	Alistair Dixon, et al.
	Group Art Unit	
(use as many sheets as necessary)	Examiner Name	

Attorney Docket Number

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	172
81		PCT International Search Report PCT/US00/18347	
		N. S. DUESBERY, et al., "MEK Wars, a new front in the Battle Against Cancer", Nature Medicine, July 1999, pp 736-737, Vol. 5, No. 7	
		J. V. DUNCIA, et al., "MEK Inhibitors: The Chemistry and Biological Activity of U0126, Its Analogs, and Cyclization Products", Bioorganic & Medicinal Chemistry Letters, 1998, pp 2839-2844, No. 8	
		A.N. GAIDUKEVICH, et al., "Synthesis and Biological Activity of N-Phenylanthranilic Acid Derivatives", STN Chemical Abstracts, September 16, 1985, Vol. 1, No. 103, Abstract Only	
		R. J. GRYGLEWSKI, "Structure-activity Relations of Some Prostaglandin Synthetase Inhibitors", Database Chemabs, 1974, Accession No. 83:126083 Abstract Only	
		M. KHALIFA, et al., "Synthesis and Biologgical Activity of Certain Derivatives of 2,4-Doixo-1,2,3,4-tetrahydroquinazoline* Part 2", Egypt J. Chem., 1982, pp 285-291, Vol. 25, No. 3	
		M. KHALIFA, et al., "Synthesis and Biological Activity of Certain Derivatives of 2,4-Dioxo-1,2,3,4-tetrahydroquinazoline", Pharmazie, 1982, pp 115-117, Vol. 37, No. 2	
		N. A. MOKHORT, "Dependence Between Structure, Anitinflammatory, Analgesic, and Antipyretic Actions in N-aromatic Derivatives of Anthranilic Acid", Chemabs, 1972, Accession No. 1972:121461 Abstract Only	
		RU-RONG JI, et al., "Nociceptive-specific Activation of ERK in Spinal Neurons Contributes to Pain Hypersensitivity", Nature Neuroscience, December 1999, pp 1114-1119, Vol. 2, No. 12	
SH		I. S. SHUL'GA, et al., "Synthesis and Physicochemcial and Biological Properties of Diphenylamine-2-carboxylic Acid Derivatives", STN Chemical Abstracts, October 24, 1988, Vol. 17, No. 109 Abstract Only	

				
Examiner			Date	0 1
	<i> </i>		Date	/
Signature	1 1 1 m 1		Considered	5/2/101
				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box 🛶	—	ı
7		ı

PTC/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

C mplete if Known Substitute for form 1449B/PTO **Application Number** 10/031180 **INFORMATION DISCLOSURE** January 16, 2002 **Filing Date** Alistair Dixon, et al. STATEMENT BY APPLICANT First Named Inventor Group Art Unit Examiner Name (use as many sheets as necessary) **Attorney Docket Number** A0000096-01-SMH Sheet of

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	72
SH		ALESSI, Dario R., et al., "PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo", J. Biol. Chem., 1995, pp 27489-27494, Vol. 270, No. 46	
		HWANG, Daniel, et al., "Expression of Mitogen-Inducible Cyclooxygenase Induced by Lipopolysaccharide: Mediation through both mitogen-activated protein kinase and NF-KB signaling pathways in macrophages", Biochem Pharm, 1997, pp 87-96, Vol. 54, Issue 1	
		LARRIVEE, Jean-François, et al., "Role of the Mitogen-Activated Protein Kinases in the Expression of the Kinin B1 Receptors Induced by Tissue Injury", J Immunol, 1998, pp 1419-1426, Vol. 160, No. 3	
m		POLAKIEWICZ, Roberto D., et al., "A Mitogen-activated Protein Kinase Pathway Is Required for μ-Opioid Receptor Desensitization", J. Biol. Chem., 1998, pp 12402-12406. Vol. 273, No. 20	
		P _K	
		TED APA CEIVA	
		TECH CENTER 18 2003	
•		1000/2900	
			-
Examiner Signature		Date Considered 2/22/0J	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.